Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Nov 5, 2026

Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting

-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefi
Press release cover image

Nov 5, 2026

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatmentUpdated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were
Press release cover image

Nov 5, 2026

Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin

All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation at the 68th ASH Annual Meeting on December 14, 2026 SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kamau Therapeutics, a clinical-stage company creating medicines that endure by precisely engineering patients’ own blood stem cells, today announced that new clinical data, inclu
Press release cover image

Nov 4, 2026

UCB advances its digital antibody engineering program with new Cradle collaboration

Collaboration adds Cradle's end-to-end platform to UCB's computational capabilities, supporting faster discovery of complex therapies for severe diseasesBRUSSELS and AMSTERDAM, Nov. 4, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, and Cradle, which builds a leading AI-driven protein design and engineering platform, today announced a strategic collaboration. The collaboration is the latest step in UCB's expanding digital antibody discovery and engineering program, which draws on t
Press release cover image

Nov 3, 2026

MoleculeMind's New MMDesign Technical Report Demonstrates 94.7% Campaign Success Rate Across Diverse Molecular Targets and Modalities

SHANGHAI, Nov. 3, 2026 /PRNewswire/ -- MoleculeMind, an AI-native biological infrastructure company, recently released a new technical report detailing the performance of MMDesign, its AI-powered de novo molecular design platform which demonstrated a 94.7% campaign success rate across diverse biological targets and molecular modalities. The report presents experimental validation results from 19 design campaigns spanning 18 distinct targets and two molecular modalities: nanobodies and macrocycli
Press release cover image

Nov 3, 2026

QUANTRO Therapeutics secures key Austrian research grant to build its AI-powered drug discovery platform

Vienna, Austria, Nov. 03, 2026 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics GmbH, a pioneer in the discovery of transcription factor targeting therapies, announced today that the company received a 12-month, non-dilutive research grant awarded by the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft, FFG) to support the development of ASCEND, its AI-driven medicinal chemistry platform underpinning the company’s drug discovery pipeline. ASCEND couples QUANTRO’s capability to leve
Press release cover image

Nov 3, 2026

Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery

Collaboration aims to discover and develop novel small molecule therapeutics against two targets designated by MerckVANCOUVER, British Columbia--(BUSINESS WIRE)--#AIDD--Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to design and optimize novel small molecule candidates against two undisclosed targets.Under the agreement, Variational AI will us
Press release cover image

Nov 3, 2026

SCIEX Launches LeadScape Compatible with SCIEX OS Software to Accelerate High-Throughput Drug Candidate Evaluation

New software automates compound optimization and ADME workflows, helping pharmaceutical scientists move from analysis to confident decisions fasterMARLBOROUGH, Mass.--(BUSINESS WIRE)--SCIEX, a Danaher company and leader in life science analytical technologies, today announced the launch of LeadScape® compatible with SCIEX OS software, a new high-throughput workflow solution that accelerates drug candidate evaluation. Developed by Sound Analytics, the software automates compound optimization and
A minimalist representation of a drug compound molecule on a light gray background.

Nov 1, 2026

Anthropic's next big AI business is life sciences, from biotech research to drug discovery

Anthropic is expanding its focus from coding to life sciences, as outlined in its recent S-1 filing ahead of an IPO.The document portrays Anthropic's ambitions in the life sciences sector, emphasizing the potential for AI to revolutionize biological and medicinal research. The company aims to leverage its advanced AI models to tap into the substantial financial resources of the pharmaceutical industry, which is projected to exceed $2 trillion in global spending by 2026. Notably, Anthropic's fili
A flat design of a drug compound silhouette on a solid background.

Oct 31, 2026

Anthropic's next big AI business is life sciences, from biotech research to drug discovery

Anthropic is pivoting towards life sciences, aiming to leverage AI in biotech and drug discovery as part of its broader business strategy ahead of an upcoming IPO.The company's recent S-1 filing highlights its vision for integrating AI into biological research, positioning itself as a key player in accelerating scientific innovation. Anthropic anticipates that advancements in life sciences will not only enhance public perception of AI but also drive financial growth, tapping into an industry tha
A vial of personalized cancer vaccine EVX-01 in a laboratory setting

Oct 31, 2026

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion has been awarded the prestigious International Prix Galien Award for its innovative AI-Immunology™ platform, recognized as the best digital health solution.This accolade, presented at the American Museum of Natural History in New York City, underscores the significance of AI-Immunology™, which employs artificial intelligence to decode the human immune system, paving the way for novel immunotherapies targeting cancer, autoimmune, and infectious diseases. The platform has already demonstra
Press release cover image

Oct 30, 2026

Life Extension and PIPA Search 600,000 Molecules in 13 Weeks and Identify New Bioactive Candidates

Powered by PIPA's Food Innovation Operating System (FIOS®), this landmark collaboration demonstrates a new model for ingredient discovery. A brand can now search an entire compound space, rule out unsafe or unviable candidates before the lab, and reach validation in a single quarter.FORT LAUDERDALE, Fla. and DAVIS, Calif., Oct. 30, 2026 /PRNewswire/ -- Life Extension and PIPA today announced the results of a 13‑week AI‑driven discovery collaboration aimed at identifying a new generation of natur